ArticleAntimicrobial agents and chemotherapy2005
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 139 citations in OpenAlex.
- Effect of antiretroviral therapy on malaria incidence in HIV-infected Ugandan adults.AIDS (London, England) · 2017Trial
- Trial
- Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.British journal of clinical pharmacology · 2015Trial
- Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women.The Journal of infectious diseases · 2014Trial
- Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.Journal of acquired immune deficiency syndromes (1999) · 2014Trial
- Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies.The American journal of tropical medicine and hygiene · 2013Trial
- Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.The New England journal of medicine · 2012Trial
- HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.Antimicrobial agents and chemotherapy · 2012Trial
- Inhibition ofCurrent research in structural biology · 2024Article
- Effect of HIV aspartyl protease inhibitors on experimental infection with a cystogenic Me49 strain ofPathogens and global health · 2022Article
- Signal peptide peptidase: a potential therapeutic target for parasitic and viral infections.Expert opinion on therapeutic targets · 2022Review
- Initiation of anti-retroviral/Trimethoprim-Sulfamethoxazole therapy in a longitudinal cohort of HIV-1 positive individuals in Western Kenya rapidly decreases asymptomatic malarial parasitemia.Frontiers in cellular and infection microbiology · 2022Article
- Multipurpose Drugs Active Against BothFrontiers in cellular and infection microbiology · 2021Review
- Modulation of Triple Artemisinin-Based Combination Therapy Pharmacodynamics byACS pharmacology & translational science · 2020Article
- Repurposing Drugs to Fight Hepatic Malaria Parasites.Molecules (Basel, Switzerland) · 2020Review
- Malaria parasite plasmepsins: More than just plain old degradative pepsins.The Journal of biological chemistry · 2020Review
- In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum.Biomedica : revista del Instituto Nacional de Salud · 2020Article
- Synthesis and Application of 1,2-Aminoalcohols with Neoisopulegol-Based Octahydrobenzofuran Core.Molecules (Basel, Switzerland) · 2019Article
- HIV protease inhibitors block parasite signal peptide peptidases and prevent growth of Babesia microti parasites in erythrocytes.Biochemical and biophysical research communications · 2019Article
- Health Considerations for HIV-Infected International Travelers.Current infectious disease reports · 2019Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Aspartic proteases play key roles in the biology of malaria parasites and human immunodeficiency virus type 1 (HIV-1). We tested the activity of seven HIV-1 protease inhibitors against cultured Plasmodium falciparum. All compounds inhibited the development of parasites at pharmacologically relevant concentrations. The most potent compound, lopinavir, was active against parasites (50% inhibitory concentration [IC50], 0.9 to 2.1 microM) at concentrations well below those achieved by ritonavir-boosted lopinavir therapy. Lopinavir also inhibited the P. falciparum aspartic protease plasmepsin II at a similar concentration (IC50, 2.7 microM). These findings suggest that use of HIV-1 protease inhibitors may offer clinically relevant antimalarial activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.